BI
NAMS icon

BVF Inc’s NewAmsterdam Pharma NAMS Stock Holding History

BVF Inc’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-59,065
Closed -$1.21M – 49
2025
Q1 		$1.21M Buy
+59,065
New +$1.31M 0.05% 48
2024
Q4 		– Sell
-1,521,948
Closed -$25.3M – 57
2024
Q3 		$25.3M Hold
1,521,948
– – 0.74% 29
2024
Q2 		$29.2M Hold
1,521,948
– – 0.82% 31
2024
Q1 		$36M Hold
1,521,948
– – 0.99% 28
2023
Q4 		$17M Hold
1,521,948
– – 0.43% 41
2023
Q3 		$14.1M Hold
1,521,948
– – 0.38% 39
2023
Q2 		$18.1M Hold
1,521,948
– – 0.5% 36
2023
Q1 		$20.5M Hold
1,521,948
– – 0.75% 36
2022
Q4 		$16M Buy
+1,521,948
New +$15.1M 0.68% 42

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BVF Inc's NAMS Position: Q2 2025 in Review

BVF Inc sold out of NewAmsterdam Pharma (NAMS) in Q2 2025, closing a stake of 59,065 shares — an estimated $1.21M sold.

BVF Inc first reported a position in NAMS in Q4 2022 and held it in 9 quarters. The position peaked at $36M in Q1 2024. 131 funds tracked by Wall St. Rank hold NAMS as of Q2 2025.

  • BVF Inc reported no remaining NewAmsterdam Pharma position as of Q2 2025 after selling out during the quarter.
  • BVF Inc sold 59,065 NewAmsterdam Pharma shares in Q2 2025, an estimated $1.21M.
  • BVF Inc first reported a position in NewAmsterdam Pharma in Q4 2022 and held it in 9 quarters.
  • BVF Inc's NewAmsterdam Pharma position peaked at $36M in Q1 2024.
  • 131 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2025.

Based on BVF Inc's 13F filing for Q2 2025, filed 14 Aug 2025.